Remington Ruth, Chan Amy, Paskavitz James, Shea Thomas B
Department of Nursing, University of Massachusetts Lowell, Lowell, Massachusetts, USA.
Am J Alzheimers Dis Other Demen. 2009 Feb-Mar;24(1):27-33. doi: 10.1177/1533317508325094. Epub 2008 Dec 3.
Recent studies demonstrated efficacy of a vitamin/ nutriceutical formulation (folate, vitamin B12, alpha-tocopherol, S-adenosyl methionine, N-acetyl cysteine, and acetyl-L-carnitine) for mild to moderate Alzheimer's disease. Herein, we tested the efficacy of this formulation in a small cohort of 12 institutionalized patients diagnosed with moderate-stage to later-stage Alzheimer's disease. Participants were randomly separated into treatment of placebo groups. Participants receiving the formulation demonstrated a clinically significant delay in decline in the Dementia Rating Scale and clock-drawing test as compared to those receiving placebo. Institutional caregivers reported approximately 30% improvement in the Neuropyschiatric Inventory and maintenance of performance in the Alzheimer's Disease Cooperative Study-Activities of Daily Living for more than 9 months. This formulation holds promise for delaying the decline in cognition, mood, and daily function that accompanies the progression of Alzheimer's disease, and may be particularly useful as a supplement for pharmacological approaches during later stages of this disorder. A larger trial is warranted.
近期研究表明,一种维生素/营养制剂(叶酸、维生素B12、α-生育酚、S-腺苷甲硫氨酸、N-乙酰半胱氨酸和乙酰左旋肉碱)对轻至中度阿尔茨海默病有效。在此,我们在一小群12名被诊断为中度至晚期阿尔茨海默病的机构化患者中测试了该制剂的疗效。参与者被随机分为治疗组和安慰剂组。与接受安慰剂的参与者相比,接受该制剂的参与者在痴呆评定量表和画钟试验中的衰退出现了临床上显著的延迟。机构护理人员报告称,神经精神科量表评分提高了约30%,且在阿尔茨海默病协作研究日常生活活动量表中的表现维持了9个月以上。该制剂有望延缓阿尔茨海默病进展过程中认知、情绪和日常功能的衰退,并且在该疾病后期作为药物治疗方法的补充可能特别有用。有必要进行更大规模的试验。